AbbVie Inc. (BMV:ABBV)

Market Cap	6.48T
Revenue (ttm)	1.10T
Net Income (ttm)	70.21B
Shares Out	n/a
EPS (ttm)	39.61
PE Ratio	92.36
Forward PE	14.97
Dividend	127.30 (3.44%)
Ex-Dividend Date	Jul 15, 2025

Volume	18
Average Volume	961
Open	3,700.00
Previous Close	3,690.00
Day's Range	3,700.00 - 3,700.00
52-Week Range	3,343.00 - 4,529.31
Beta	0.50
RSI	61.01
Earnings Date	Jul 25, 2025

About Accolade

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.